contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-presentation-of-cinclus-pharmas-fourth-quarter-report-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Cinclus Pharma is a Swedish clinical-stage pharmaceutical company. The company is active in the development of molecules for the treatment of acid-related diseases. The company's lead drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and is headquartered in Stockholm, Sweden.

Cinclus Pharma

Cinclus Pharma’s fourth quarter report for October – December 2025 will be published on Wednesday, February 18, 2026, at 08:00 am CET. The company will host a live presentation the same day ...

<div class="mfn-preamble"><p><strong>Cinclus Pharma’s fourth quarter report for October – December 2025 will be published on Wednesday, February 18, 2026, at 08:00 am CET. The company will host a live presentation the same day at 10:00 am CET.</strong></p></div><div class="mfn-body"><p>The report is presented by CEO Christer Ahlberg, Interim CFO Patrik Norgren and R&amp;D Director Margit Mahlapuu. The presentation includes a Q&amp;A session.<br>&nbsp;<br>If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions.<br>&nbsp;<br><a rel="noopener" href="https://swe01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcinclus-pharma.events.inderes.com%2Fq4-report-2025&amp;data=05%7C02%7Chenrik.vikstrom%40cordcom.se%7Cd07f00ff746e4fd2b90608de5996fb3f%7C0c6211bb1e374febb7543f32df36d858%7C0%7C0%7C639046702236617693%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=9I1%2FGo56HHZOAz%2FCu0wCp%2FXBGrcfR1saKxbLy4oY0%2F8%3D&amp;reserved=0">https://cinclus-pharma.events.inderes.com/q4-report-2025</a><br>&nbsp;<br>If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.&nbsp;<br>&nbsp;<br><a rel="noopener" href="https://swe01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fevents.inderes.com%2Fcinclus-pharma%2Fq4-report-2025%2Fdial-in&amp;data=05%7C02%7Chenrik.vikstrom%40cordcom.se%7Cd07f00ff746e4fd2b90608de5996fb3f%7C0c6211bb1e374febb7543f32df36d858%7C0%7C0%7C639046702236646791%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=BY0k4zPsldnI1JfInNVrz4zICa8GjK13M4z6SrWYosg%3D&amp;reserved=0">https://events.inderes.com/cinclus-pharma/q4-report-2025/dial-in</a><br>&nbsp;<br>The report, the presentation and a recorded version of the presentation will also be available on the company's website:&nbsp;<a rel="noopener" href="https://cincluspharma.com/investors/financial-reports/">Financial Reports | Cinclus Pharma</a><br><strong>&nbsp;</strong></p></div><div class="mfn-footer mfn-contacts mfn-5e7308741e14"><p><strong class="mfn-heading-1">For additional information, please contact:</strong></p><hr><p>Christer Ahlberg, CEO<br>Phone: +46 70 675 33 30<br>e-mail: <a rel="noopener" href="mailto:maria.engstrom@cincluspharma.com">christer.ahlberg@cincluspharma.com</a></p><p>Henrik Vikström, IR<br>Phone: +46 70 952 80 06<br>e-mail: <a rel="noopener" href="mailto:maria.engstrom@cincluspharma.com">henrik.vikström@cincluspharma.com</a></p></div><div class="mfn-footer mfn-bd4a0982d054"><p><strong class="mfn-heading-1">About Cinclus Pharma</strong></p><hr><p>Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. The first Phase III study commenced in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit <a rel="noopener" href="http://www.cincluspharma.com">www.cincluspharma.com</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/073d5af0-7f8b-4917-86ed-daad192e4cec/invitation-to-presentation-of-cinclus-pharmas-fourth-quarter-report-2025.pdf" class="mfn-generated mfn-primary">Invitation to presentation of Cinclus Pharma’s fourth quarter report 2025</a></p></div>